Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Feeling better, fast — a new study shows that more than half of women treated with gepotidacin, a first-in-class oral antibiotic, saw UTI symptom relief within just 24 hours. Published in JAMA Network Open, the phase 3b trial of 97 patients found nearly 80% improved by 48 hours and 90% achieved full resolution by day 10. Experts say it's a promising option as antibiotic resistance narrows treatment choices — but caution against overuse.
Gepotidacin delivers fast UTI relief, but experts urge careful use
A new phase 3b trial published in JAMA Network Open found that gepotidacin, a first-in-class oral antibiotic FDA-approved in 2025, provided symptom relief to more than half of women with uncomplicated UTIs within just 24 hours of starting treatment. The single-arm study enrolled 97 girls and women aged 12 and older, each receiving 1,500 mg of gepotidacin twice daily for five days.
The results are encouraging, especially for patients with recurrent UTIs facing drug-resistant bacteria — a scenario that can leave clinicians with few oral options before resorting to IV antibiotics. Still, experts caution that without a comparison group, the data can't confirm gepotidacin works faster than existing antibiotics. Overuse, they warn, risks breeding resistance to this new drug as well.
By the Numbers
Why it matters: As antibiotic resistance grows, gepotidacin offers a valuable new oral option for UTI treatment — but antimicrobial stewardship principles remain critical to preserving its effectiveness long-term.
